psmarketresearch1’s blog

All about market research update

Medical Device Connectivity Industry Analysis, Size, Growth and Forecast to 2023


The global medical device connectivity market is witnessing considerable growth due to increasing implementation of electronic health records and health information exchange systems, increasing regulations for improving healthcare quality, growing demand for home healthcare due to increasing geriatric population, improved diagnosis of patient, and increasing healthcare IT initiatives. Moreover, increasing prevalence of chronic diseases, increasing emphasis on care quality and patient safety, and increasing need to reduce healthcare costs through a connected healthcare environment are supporting the demand of medical device connectivity. The medical device connectivity aids in data analytics and growing adoption of telehealth solutions are also driving the growth of the market. Based on product type, the market for service segment is expected to grow at the faster rate compared to solution during the forecast period, due to increasing requirement for maximum consumption of connectivity solutions by the user, increasing regulatory requirements and healthcare reforms, increasing implementation of healthcare information exchange system, and increasing need for effective implementation.

Explore Report at:

The growing adoption of telehealth solutions, shift of point-of-care diagnostics from hospitals to home care and increasing need for interoperability due to medical devices connectivity solutions are some of the major trends for the global medical device connectivity market.

The increasing female aging population is propelling the growth of the global Hysteroscope market. As reported by UN DESA (United Nation Department of Economic and Social Affairs) in the year 2013, the elder population is predominantly female. As women tend to live longer than men, while older women have outnumbered older men almost everywhere in the world. It further reported that in the year 2013, globally, there were 85 men per 100 women in the age group 60 years or plus; and 61 men per 100 women in the age group 80 years or plus. The elderly population is more susceptible to gynaecological problems, such as abnormal uterine bleeding, fibroids, and polyps, as compared to adults, which is fuelling the demand of the global hysteroscope market. Aging in females leads to changes in hormones leading to irregular menses, which contributes to the demand for Geographically, North America has been the largest and fastest growing market for medical device connectivity, owing to better accessibility to technologies, increasing demand for eHealth solutions, increasing funding for innovation in medical sector, increasing focus on quality of care and patient safety, and increasing government initiatives and support in the region. The U.S. contributed largest revenue to the North American as well as global medical device connectivity market. The increasing implementation of electronic health record systems, growing geriatric population, and increasing need for data analytic in healthcare are the key growth driving factor for the U.S. medical device connectivity market.

Explore Report Sample at:

The key players operating in the global medical device connectivity market are GE Healthcare, Cerner Corporation, Cisco Systems Inc., Qualcomm Inc., Koninklijke Philips N.V., Medtronic Plc., Infosys Limited, and Digi International Inc.

Medical Image Management Industry Analysis, Demand, Forecast to 2023


The global medical image management market is witnessing considerable growth due to technological advancements in diagnostic imaging modalities and image management solutions, increasing usage of imaging equipment, and increasing adoption of Vendor Neutral Archive (VNA). Moreover, increasing investment in the medical imaging, increasing adoption of imaging management system by small imaging centers and hospitals, and rapidly growing big data in healthcare are supporting the demand for medical image management systems. The increasing government initiatives to encourage electronic medical record adoption is further expected to boost the market. Based on product type, picture archiving and communication system (PACS) segment leads the global market in terms of size, due to technological advancements in PACS, increasing volume of imaging procedure and adoption of the PACS in new imaging segments such as mammography, endoscopy, oncology and ophthalmology. Hospitals have been the largest user of medical image management systems, owing to growing awareness about early diagnosis of diseases, increasing digitalization of patient’s data, rapid growth in adoption of EMR, and technological advancement in imaging modalities.

Explore Report at:

Rapidly increasing big data in healthcare and rapid growth in geriatric imaging volumes are also fueling the growth of the global medical image management market. Geriatric population has weakened body functions, and are more susceptible to chronic diseases. As per the United Nations Department of Economic and Social Affairs (UN-DESA) report on the global aging population, the population of people aged 60 years or above is growing with high rate. The global percentage of people aged 60 or above in 2013 was 11.7% and it is expected to reach 21.1% by the end of 2050. Further, the number of people aged 60 years and above is expected to reach approximately 437 million in China, 324 million in India, 107 million in the U.S. and 58 million in Brazil by 2050.

Explore Report Sample at:

The key players operating in the global medical image management market are McKesson Corporation, General Electric Company, Fujifilm Holdings Corporation, Siemens AG, IBM Corporation, Koninklijke Philips N.V. and AGFA-Gevaert Group.

Systemic Lupus Erythematosus Pipeline - Patent, Designation, Collaboration, and Other Developments


The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. Some of the common symptoms of systemic lupus erythematosus include oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is being treated using a combination approach as number of organs are involved. Therefore, various combination therapies are being used to improve quality of life of the patients. Also, combining novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

Explore Report Description at:

Seattle Genetics, Inc. is using antibody-drug conjugate (ADC) technology platform for the development of Brentuximab vedotin for the treatment of systemic lupus erythematosus. The technology platform employs a monoclonal antibody specific for a tumor-associated antigen, plus synthetic cytotoxic (cell-killing) agents connected by stable linker systems designed to securely bind the cytotoxic agent to the antibody and then release the agent within the targeted cell.

The research also found that various companies have collaborated for the development of systemic lupus erythematosus pipeline.

Explore Report Sample at:

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.

Clostridium Difficile- Associated Diarrhea Therapeutics Pipeline Analysis 2017

The prevalence of clostridium difficile associated diarrhea has been increasing all across the world on account of unchecked use of antibiotics and laxatives by people, which creates a suitable medium for the growth of the bacteria. Clostridium Difficile is a commonly noticed disease in people above 65 years of age, as they tend to consume antibiotics and laxatives for easy and effective bowel movement. The therapeutic pipeline of clostridium difficile associated diarrhea is growing with the involvement of various pharmaceutical companies that are working towards the development of drugs or therapeutic agentsto be used for the treatment of clostridium difficile associated diarrhea. According to a paper published by NCBI, in 2012, clostridium difficile associated diarrhea is responsible for causing diarrhea to 3 million people in the U.S. Clostridium difficile associated diarrhea (CDAD) is also caused by nosocomial infection, acquired from hospitals due to presence of different viruses and pathogens in the hospitals. It is projected that the number of cases related to clostridium difficile associated diarrhea would increase in the future, with increase in unrestrained consumption of antibiotics.

Explore Report at:

Clostridium difficile is a rod-shaped gram positive bacterium, which is responsible for causing diarrhea. It is the most common type of infection, and is usually found more in developing countries such as India, Iran, Pakistan, Afghanistan, Iraq, Nepal and China. Some of the symptoms of clostridium difficile associated diarrhea include severe colitis, fever, abdominal pain, dehydration, rapid heart rate, nausea, blood in the stool and loss of appetite. Clostridium difficile has been reported as more common in women and older patients.

Request for Table of Content at:

Some of the companies having a pipeline of clostridium difficile associated diarrhea (CDAD) therapeutics include Astella pharma Inc.,Merck Sharp & Dohme Corp,Actelion Inc., Da volterra Inc.,Eliy-lilly& Company, Gilead Sciences, Inc., Galapagos NV, Astellas Pharma, Abbvie, Inc., Bexalta US, Inc., Optimer pharmaceutical LLC.

Fragile-x Syndrome Therapeutics Pipeline Analysis 2017 - Designation, Collaboration, and Other Developments


Due to lack of awareness among people regarding genetic disorders which leads to mutations in one’s DNA, the prevalence of fragile-x syndrome is increasing, across the globe. Smoking, alcohol consumption during pregnancy and hereditary disorders are few of the primary reasons to for the increase in prevalence of fragile-x syndrome. The therapeutic pipeline of fragile-x syndrome is expected to grow more rapidly in the future on account of active involvement of pharmaceuticals & biotechnology companies carrying out research programs to develop effective therapeutic agents or drugs for eradicating fragile-x syndrome. According to a study conducted by Centers for Disease Control and Prevention (CDC) in 2012, around one female in every 151 females & one male in every 468 males in the U.S., was affected by fragile-x syndrome. Moreover, according to the study, occurrence of fragile-x syndrome is higher in females as compared to males.  

Explore Report at:

Fragile-x syndrome is a genetic disorder that affects the development and learning capabilities of an individual. It is also called as Marker-x syndrome and Martin-Bell syndrome. Fragile-x syndrome causes trinucleotide repeat in Fragile-x mental retardation 1(FMR-1) gene present on X chromosome. This gene is responsible for making a protein called Fragile-x mental retardation protein (FMRP), which is required for normal neural development. In case of an individual suffering from fragile-x syndrome, production of FMRP is constrained due to the repetition of CGG (trinucleotide) in FMR1 gene. The symptoms associated with fragile-x syndrome are mental retardation, learning disability, impulsiveness, stuttering, development delays, seizures, depression, hyperactivity, etc.

Request for Table of Content at:

Some of the companies having a pipeline of Fragile-x syndrome therapeutics include Ovid therapeutics, Marinus pharmaceuticals, Neuren pharmaceuticals, Bellus health Inc., AMO pharmaceuticals, Eli-lly& co., Anavex Life Sciences Corp., Kareus Therapeutics, and Zynerba Pharmaceuticals, Inc.

Phosphatidylinositol 3-Kinase Inhibitors Pipeline Analysis 2017


The PI3K inhibitors pipeline analysis report covers approximately 37 active drug candidates in different stages of development.

Phosphatidylinositol 3-kinases (PI3K) are lipid kinases that are involved in cell regulation, including cell survival, proliferation and differentiation. They act as intermediate molecules in PI3K/AKT/mTOR signaling pathway by sending chemical messengers from cell surface to cytoplasm. These signals activate multiple effector kinase pathways, resulting in survival and growth of normal cells. Phosphatidylinositol 3-kinases is categorized on the basis of classes as class I, II and III, on the basis of structure of the PI3K, based on the specificities of the substrate as well as on the basis of lipid end-product’s nature. Bases on structure, Phosphatidylinositol 3-kinases has four different forms PI3K alpha, PI3K beta, PI3K gamma and PI3K delta.

Explore Report Description at: 

In March 2017, Bayer AG presented clinical results of Phosphoinositide 3-kinase (PI3K)-targeting drug candidate Copanlisib in Phase II CHRONOS-1 trial, evaluating patients with relapsed or refractory indolent non-Hodgkin's lymphoma (iNHL), trial with NCT ID 01660451. The results across all patient groups showed an objective response rate (ORR) of 59.2%, with a 12% complete response (CR) rate and a median duration of response (DOR) of more than 98 weeks, or 687 days (range 0-687).

The research found that different companies engaged in manufacturing of PI3K inhibitors are collaborating. One of the collaborations occurred in November 2016 between Verastem, Inc. and Infinity Pharmaceuticals, Inc.

Explore Report Sample at:

The major players for PI3K inhibitors pipeline include, but are not limited to, Novartis AG, Genentech, Inc., SignalRX Pharmaceuticals Inc. and others.

Nasopharyngeal Cancer Therapeutics Pipeline - Collaboration and Other Developments


Nasopharyngeal cancer therapeutic pipeline analysis is likely to grow mainly due to the rising prevalence of nasopharyngeal cancer, globally. Some of the main factors driving the pipeline analysis for nasopharyngeal cancer includes increasing geriatric population, rising tobacco and alcohol consumption and increasing prevalence of nasopharyngeal cancer, untapped market as being a rare form of head and neck cancer and increasing health awareness. According to American Cancer Society, the nasopharyngeal cancer is more common in some parts of North Africa and Asia, particularly in Southern China. It is also more common in countries such as Canada and Alaska and among some immigrant groups in the U.S., such as recent Chinese immigrants. Nasopharyngeal cancer is found to be more prevalent in males as compared to females.

Explore Report at:

Nasopharyngeal cancer is the rarest form of head and neck cancer. Nasopharyngeal cancer is the tumor that occurs in nasopharynx which is the upper part of the throat behind the nose and near the base of skull. Two different types of tumors that can develop in nasopharynx include benign tumors and malignant tumors. Some of the risks factors for nasopharyngeal cancer include salt-cured fish and meat rich diet, epstein-barr viral infection and increasing tobacco and alcohol consumption. The disease occurs usually more in people who are under 55years of age and have a family history of nasopharyngeal cancer or have the chances to develop Epstein-barr viral infection. The symptoms of nasopharyngeal cancer include blurred vision, ear infection, headache, nose bleeding, lump in neck and numbness. Nasopharyngeal cancer is diagnosed by consulting an otolaryngologist for the physical examination. Further, chest X-ray, CT scan, MRI, ultrasound, blood tests, Epstein-barr viral infection testing and biopsy are done for the confirmation of the disease. The treatment for nasopharyngeal cancer includes, chemotherapy, radiation therapy, surgery and biological drug treatment.

Request for Table of Content at:

Some of the companies having a pipeline of nasopharyngeal cancer therapeutics include Atara Biotherapeutics, Inc., AVEO Pharmaceuticals, Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, arGEN-X BVBA, Merck & Co., Inc., Tessa Therapeutics Pte Ltd.